Contribute Try STAT+ Today

Drugs called immune checkpoint inhibitors have transformed treatment of many types of tumors, but metastatic lung cancer has proven more challenging: While these medications have significantly extended survival for some patients, most still do not respond or develop resistance quickly. Now a small proof-of-concept study published in Nature Medicine shows that a new form of immunotherapy using a patient’s own immune cells may bring about durable responses for some people with advanced non-small cell lung cancer (NSCLC).

Patients in the small Phase 1 pilot trial were treated with tumor-infiltrating lymphocytes (TILs), which have previously brought about durable remissions in studies of patients with some other cancers but had not previously been tested in metastatic lung cancer. TILs are naturally found in solid tumors and have the ability to kill cancer cells, but the body doesn’t produce enough of them. So the researchers extracted the cells from tumors and grew billions of copies in lab dishes before transferring them back into the patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment